1. Generics Bulletin
  2. >>Leadership

Sanofi’s Jacqmin Joins Stada As Cron Departs

Stéphane Jacqmin Becomes Head Of Emerging Markets For The German Firm From 1 January

 
• By Dave Wallace

Stada has announced a change in management for its emerging markets division, with Sanofi’s Stéphane Jacqmin joining the firm from the start of 2023 to replace Carsten Cron, who is leaving the German generics and biosimilars giant for pastures new.

Emerging markets display screen graphics
Stada has named Stéphane Jacqmin as head of emerging markets • Source: Shutterstock

Stada’s emerging markets business will be under new management from the start of 2023, after the German generics and biosimilars giant announced the appointment of Stéphane Jacqmin to take over from Carsten Cron as head of emerging markets.

Jacqmin – who most recently served as regional head of Latin America at Sanofi Consumer Healthcare – will take the position from 1 January and would offer Stada “extensive leadership and management experience in consumer healthcare and fast-moving consumer goods settings across multiple

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

 
• By Dave Wallace

Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.

Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

More from Generics Bulletin